MA43556A - Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci - Google Patents

Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci

Info

Publication number
MA43556A
MA43556A MA043556A MA43556A MA43556A MA 43556 A MA43556 A MA 43556A MA 043556 A MA043556 A MA 043556A MA 43556 A MA43556 A MA 43556A MA 43556 A MA43556 A MA 43556A
Authority
MA
Morocco
Prior art keywords
antibody
combinations
tlr4 modulator
tlr4
modulator
Prior art date
Application number
MA043556A
Other languages
English (en)
Inventor
Christopher John Francis
Hua-Xin Gao
Yufeng Li
Niranjan Yanamandra
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA43556A publication Critical patent/MA43556A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA043556A 2015-08-06 2016-06-03 Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci MA43556A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562201828P 2015-08-06 2015-08-06
US201562247488P 2015-10-28 2015-10-28
US201662300400P 2016-02-26 2016-02-26
US201662322906P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
MA43556A true MA43556A (fr) 2021-03-24

Family

ID=56131579

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043556A MA43556A (fr) 2015-08-06 2016-06-03 Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci

Country Status (21)

Country Link
US (2) US20170275371A1 (fr)
EP (1) EP3331560A1 (fr)
JP (2) JP2018525378A (fr)
KR (1) KR20180032641A (fr)
CN (1) CN108025073A (fr)
AU (1) AU2016304401B2 (fr)
BR (1) BR112018002530A2 (fr)
CA (1) CA2994910A1 (fr)
CL (1) CL2018000303A1 (fr)
CO (1) CO2018001238A2 (fr)
CR (1) CR20180080A (fr)
DO (1) DOP2018000034A (fr)
EA (1) EA201890457A1 (fr)
HK (1) HK1249410A1 (fr)
IL (1) IL257067A (fr)
MA (1) MA43556A (fr)
MX (1) MX2018001515A (fr)
PH (1) PH12018500254A1 (fr)
TW (1) TW201716084A (fr)
WO (1) WO2017021791A1 (fr)
ZA (1) ZA201800468B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
WO2018009916A1 (fr) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Conjugués d'adjuvant d'anticorps
WO2019133647A1 (fr) * 2017-12-29 2019-07-04 Thevax Genetics Vaccine Co., Ltd. Combinaison d'un vaccin à protéine de fusion avec un anticorps anti-ox40 destinée à être utilisée pour déclencher des réponses immunitaires spécifiques de l'antigène
WO2020030570A1 (fr) * 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinaisons d'un anticorps ox40 et d'un modulateur de tlr4 et leurs utilisations
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2020228828A1 (fr) * 2019-05-15 2020-11-19 郑州威瑞生物技术有限公司 Composition pour induire l'activité des cellules immunitaires et méthode pour traiter des maladies utilisant celle-ci
TW202233200A (zh) * 2020-11-11 2022-09-01 日商第一三共股份有限公司 新穎胺基烷基葡萄胺糖苷4-磷酸衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1284740B1 (fr) 2000-05-19 2008-05-21 Corixa Corporation Traitement prophylactique et therapeutique de maladies infectieuses allergiques rt autoimmunes avec des composes a base de monosaccharides
JP4843181B2 (ja) 2000-08-04 2011-12-21 コリクサ コーポレイション 免疫エフェクター化合物
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US7288640B2 (en) 2002-07-08 2007-10-30 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
AU2003300184B8 (en) * 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
MX339964B (es) * 2010-08-23 2016-06-17 Board Of Regents The Univ Of Texas System * Anticuerpos anti-ox40 y metodos para usarlos.
GB201101331D0 (en) * 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
KR101685262B1 (ko) * 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
EP2659906A1 (fr) * 2012-05-01 2013-11-06 Affiris AG Compositions
MX2016007965A (es) * 2013-12-17 2016-10-28 Genentech Inc Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.

Also Published As

Publication number Publication date
US20170275371A1 (en) 2017-09-28
ZA201800468B (en) 2019-07-31
JP2021121622A (ja) 2021-08-26
AU2016304401B2 (en) 2019-05-16
HK1249410A1 (zh) 2018-11-02
CL2018000303A1 (es) 2018-07-06
AU2016304401A1 (en) 2018-02-15
US20190338042A1 (en) 2019-11-07
CR20180080A (es) 2018-04-02
EP3331560A1 (fr) 2018-06-13
CN108025073A (zh) 2018-05-11
EA201890457A1 (ru) 2018-09-28
DOP2018000034A (es) 2018-10-31
CO2018001238A2 (es) 2018-05-10
MX2018001515A (es) 2018-03-15
BR112018002530A2 (pt) 2018-09-25
IL257067A (en) 2018-03-29
JP2018525378A (ja) 2018-09-06
WO2017021791A1 (fr) 2017-02-09
CA2994910A1 (fr) 2017-02-09
PH12018500254A1 (en) 2018-08-13
KR20180032641A (ko) 2018-03-30
TW201716084A (zh) 2017-05-16

Similar Documents

Publication Publication Date Title
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA43556A (fr) Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA43955A (fr) Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA46700A (fr) Variants polypeptidiques et ses utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations